

Supplementary Table 3. Demographics and clinicopathologic characteristics of patients between groups N0 and B

Characteristic	Group N0	Group B	P-value
Age (yr)			0.575
≤60	35 (62.5)	9 (52.9)	
>60	21 (37.5)	8 (47.1)	
Sex			0.264
Male	29 (51.8)	12 (70.6)	
Female	27 (48.2)	5 (29.4)	
Hemoglobin (g/L)			0.581
≤130	29 (51.8)	7 (41.2)	
>130	27 (48.2)	10 (58.8)	
Serum albumin (g/L)			0.584
≤35	5 (8.9)	0 (0)	
>35	51 (91.1)	17 (100)	
TBIL (μmol/L)			>0.999
≤17.1	37 (66.1)	11 (64.7)	
>17.1	19 (33.9)	6 (35.3)	
ALT (U/L)			0.570
≤40	33 (58.9)	12 (70.6)	
>40	23 (41.1)	5 (29.4)	
γ-GT (U/L)			0.748
≤50	13 (23.2)	3 (17.6)	
>50	43 (76.8)	14 (82.4)	
PT (sec)			0.414
≤14	55 (98.2)	16 (94.1)	
>14	1 (1.8)	1 (5.9)	
INR			0.230
≤1.15	54 (96.4)	15 (88.2)	
>1.15	2 (3.6)	2 (11.8)	
HBsAg			>0.999
Negative	41 (73.2)	13 (76.5)	
Positive	14 (25.0)	4 (23.5)	
Missing	1 (1.8)	0 (0)	
CEA (μg/L)			0.147
≤5	39 (69.6)	8 (47.1)	
>5	17 (30.4)	9 (52.9)	
CA 125 (U/mL)			0.213
≤35	43 (76.8)	10 (58.8)	
>35	13 (23.2)	7 (41.2)	
CA 19-9 (U/mL)			0.125
≤35	19 (33.9)	2 (11.8)	
>35	37 (66.1)	15 (88.2)	
Tumor number			>0.999
1	44 (78.6)	12 (70.6)	
>1	9 (16.1)	2 (11.8)	
Missing	3 (5.3)	3 (17.6)	
Tumor size (cm)			0.560
≤5	25 (44.6)	9 (52.9)	
>5	27 (48.2)	6 (35.3)	
Missing	4 (7.2)	2 (11.8)	
Tumor type			0.444
Non-mass-forming	7 (12.5)	1 (5.9)	
Mass-forming	49 (87.5)	16 (94.1)	
Surgical margin			0.857
R0	52 (92.9)	16 (94.1)	
R1	4 (7.1)	1 (5.9)	
No. of LNs harvested			0.024
<6	37 (66.1)	6 (35.3)	
≥6	19 (33.9)	11 (64.7)	

Supplementary Table 3. Continued

Characteristic	Group N0	Group B	P-value
Vascular invasion			0.497
No	43 (76.8)	12 (70.6)	
Yes	10 (17.9)	5 (29.4)	
Missing	3 (5.3)	0 (0.0)	
Surgery time (min)			0.410
≤300	36 (64.3)	9 (52.9)	
>300	20 (35.7)	8 (47.1)	
Blood loss (mL)			0.787
≤300	32 (57.1)	9 (52.9)	
>300	24 (42.9)	8 (47.1)	
Blood transfusion			0.368
No	39 (69.6)	14 (82.4)	
Yes	17 (30.4)	3 (17.6)	
Postoperative hospital stay (day)			0.784
≤12	35 (62.5)	10 (58.8)	
>12	21 (37.5)	7 (41.2)	
Postoperative complication			0.627
No	43 (76.8)	14 (82.4)	
Yes	13 (23.2)	3 (17.7)	
Adjuvant treatment			0.106
No	53 (94.6)	14 (82.4)	
Yes	3 (5.4)	3 (17.7)	

Values are presented as number (%).

TBIL, total bilirubin; INR, international normalized ratio; LN, lymph node.